In a nutshell This analysis compared the effectiveness and safety of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors and chemotherapy in patients with mutated EGFR non-small cell lung cancer. Some background Many non-small cell lung cancer patients present with a mutated (abnormal) EGFR, which can increase the production...
Read More
In a nutshell This study examined the safety and effectiveness of oral vinorelbine (Navelbine), a new form of a standard chemotherapy treatment for stage 3 non-small cell lung cancer. Some background Because symptoms of early non-small cell lung cancer can be vague, many patients are not diagnosed until their disease is locally advanced (stage 3,...
Read More
In a nutshell The study investigated the effect of age on the outcome of patients being treated with surgery for early stage NSCLC. Some background Non small-cell lung cancer (NSCLC) is a common form of lung cancer that can be difficult to treat. Treatment for early stage (stage 1 & 2) involves lobectomy (surgery to remove part of the lung);...
Read More
In a nutshell This study investigated the relationship between the protein miR-182 and outcome of patients with non small-cell lung cancer, including the development of tumor blood supply. Some background Non small-cell lung cancer (NSCLC) is the most common type of lung cancer (80-85% of lung cancer patients) and despite improvements in treatment...
Read More
In a nutshell This study investigated the ability of mutations in the protein TP53 to predict outcome of patients with advanced NSCLC. Some background Non small-cell lung cancer (NSCLC) is a common type of lung cancer that is both difficult to treat and has a poor survival rate. A common cause associated with developing NSCLC is a mutation...
Read More
Cost Medical care for cancer is costly. In addition, there is the financial burden that patients and families face in getting to and from the best care–which may be located at medical centers far from home. The situation can seem overwhelming. Corporate Angel Network Into this dilemma, little known resources have arisen to meet this challenge. One of...
Read More
In a nutshell This study investigated using levels of the proteins MUC1 and VEGF to predict the benefit of gefitinib in patients with advanced NSCLC. Some background Non small-cell lung cancer (NSCLC) is a common type of lung cancer that can be difficult to treat. 65-75% of cases are presented at an advanced stage. Chemotherapy is often...
Read More
In a nutshell The study investigates measuring cellular CDK levels to predict the outcome of early stage-NSCLC patients. Some background Non small-cell lung cancer (NSCLC) is a common type of lung cancer that can be difficult to treat. Even early-stage NSCLC treated with surgery has a poor 5-year survival rate (65%) due...
Read More
Give light, and the darkness will disappear of itself. ~Desiderius Erasmus CancerHawk is about giving light to cancer patients and their caregivers. Started by Robyn Stoller in 2011, CancerHawk is Robyn’s way of sharing the knowledge that she gained on-the-job as caregiver to her husband. Robyn and Alan’s Story Robyn met Alan Stoller on a retreat in...
Read More
In a nutshell This study investigated the benefit of combining post-operative radiation therapy with surgery and chemotherapy for the treatment of SCLC. Some background Small cell lung cancer (SCLC) accounts for 15% of all lung cancers. In 40% of patients SCLC is diagnosed at a limited stage (present in a single lung). The standard care given...
Read MoreIn a nutshell This study compared the outcomes between the standard chemotherapy treatment for advanced non-small-cell lung cancer and a new drug, afatinib (Gilotrif, Giotrif) in Asian populations. Some background Non-small-cell lung cancer (NSCLC) is a common type of lung cancer but can be difficult to treat. Standard treatment involves...
Read More
In a nutshell The article evaluated the accuracy of YKL-40 levels to predict a patient’s response to chemotherapy for the treatment of SCLC and their cancer outcomes. Some background Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and has a low 5-year survival rate of 10-26% due to relapse (cancer...
Read More
